Secondary prevention of venous thromboembolic complications. Focus on dabigatrane
Abstract
Venous thromboembolic complications (VTEC) are a frequent pathology accompanied by high lethality. After VTEC the risk of their recurrence not equivalent for all patients remains. The anticoagulant therapy available currently effectively prevents VTEC increasing a possibility of hemorrhages. This means that at planning the secondary prevention it’s necessary to maintain the optimal balance between a possibility of recurrence of VTEC and development of hemorrhagic complications. Thus, selection of patients for secondary prevention must be accompanied by a comprehensive analysis of numerous factors as determining the possibility of VTEC recurrence as well as a risk of complications development. Warfarin is the most frequently used drug for long-term anticoagulant per os therapy, it requires frequent monitoring with periodic dose correction and strict dietary limitations. New oral anticoagulants (NOAC) are applied at a fixed dose without obligatory strict hemostasiologic control, which makes them rather attractive for continues secondary prevention of VTEC.
About the Authors
V.Y. Bogachev
Pirogov Russian Medical University
Russian Federation
Russian Federation
B. V. Boldin
Pirogov Russian Medical University
Russian Federation
Russian Federation
О.V. Djenina
First Phlebologic Center
Russian Federation
Russian Federation
V. N. Lobanov
First Phlebologic Center
Russian Federation
Russian Federation
References
1. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med, 2007, 147: 766-774.
2. Agnelli G, Becattini C. Treatment of DVT: How long is enough and how do you predict recurrence. J Thromb Thrombolysis, 2008, 25: 37-44.
3. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol, 2009, 29: 298-310.
4. Schulman S. Extension of anticoagulation after venous thromboembolism. Risk factors influencing the decision. Hamostaseologie, 2008, 28: 110-119.
5. Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med, 2008, 149: 481-490.
6. Eichinger S., Heinze G., Jandeck L.M., Kyrle P.A. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation, 2010, 121 (14): 1630-1636.
7. Tosetto A., Iorio A., Marcucci M., Baglin T., Cushman M., Eichinger S., Palareti G., Poli D., Tait R.C., Douketis J.Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thrombol Haemost, 2012, 10 (6): 1019-1025.
8. Siragusa S., Malato A., Anastasio R., et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood, 2008, 112: 511-515.
9. Kearon C., Akl E., Ornelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report Chest. 2016, 149 (2): 315-352.
10. Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis, 2010, 29: 182-191.
11. RuTz-GimTnez N, Su3rez C, Gonz3lez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost, 2008, 100: 26-31.
12. Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost, 2009, 102: 892-899.
13. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15-20.
14. Schulman S., Kakkar A., Goldhaber S. et al. for the RE-COVER II Trial Investigators. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. Circulation, 2014, 129: 764-772.
15. Schulman S., Kearon C., Kakkar A., et al. for the RE-MEDY and the RE-SONATE Trials Investigators. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. N Engl J Med, 2013, 21: 709-718.
16. Graham DJ. et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. Published online 3 October 2016. doi:10.1001/jamainternmed.2016.5954.
17. Parks A.L and Redberg R.F. Editor's Note: Comparing Non-Vitamin K Oral Anticoagulants: Where We Are Now. JAMA Intern Med. Published online 3 October 2016. doi:10.1001/jamain-ternmed.2016.6429.
Review
For citations:
Bogachev V., Boldin B.V., Djenina О., Lobanov V.N. Secondary prevention of venous thromboembolic complications. Focus on dabigatrane. Ambulatornaya khirurgiya = Ambulatory Surgery (Russia). 2017;(3-4):36-42. (In Russ.)
Views:
2110
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International.
Email this article 